Showing results (121-130 of 169) with videos related to

Sort By:
Pageof 17
The Journal of Experimental Medicine|November 15, 2022
SARS-CoV-2 Spike protein suppresses CTL-mediated killing by inhibiting immune synapse assemblyAnna Onnis, Emanuele Andreano, Chiara Cassioli, et al.
Scientific Reports|July 17, 2023
Enabling X-ray fluorescence imaging for in vivo immune cell trackingTheresa Staufer, Christian Körnig, Beibei Liu, et al.
Nanotechnology|August 12, 2011
Conductive supports for combined AFM-SECM on biological membranesPatrick L T M Frederix, Patrick D Bosshart, Terunobu Akiyama, et al.
Hepatology (Baltimore, Md.)|April 29, 2016
Coagulation parameters and major bleeding in critically ill patients with cirrhosisAndreas Drolz, Thomas Horvatits, Kevin Roedl, et al.
Clinical Nutrition (Edinburgh, Scotland)|August 13, 2025
Progression of liver fibrosis after metabolic bariatric surgery in a MASLD rat modelMagdalena Mairinger, Paula Richwien, Jakob Eichelter, et al.
Physical Review Letters|December 23, 2022
In Situ Measurement of Electron Energy Evolution in a Laser-Plasma AcceleratorS Bohlen, T Brümmer, F Grüner, et al.
Nature Nanotechnology|March 7, 2009
Early detection of aging cartilage and osteoarthritis in mice and patient samples using atomic force microscopyMartin Stolz, Riccardo Gottardi, Roberto Raiteri, et al.
United European Gastroenterology Journal|October 31, 2019
Evaluation and comparison of six noninvasive tests for prediction of significant or advanced fibrosis in nonalcoholic fatty liver diseaseKatharina Staufer, Emina Halilbasic, Walter Spindelboeck, et al.
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|March 27, 2019
MARKEDLY DELAYED INSULIN SECRETION AND A HIGH RATE OF UNDETECTED OVERT DIABETES CHARACTERIZE GLUCOSE METABOLISM IN ADULT PATIENTS WITH CYSTIC FIBROSIS AFTER LUNG TRANSPLANTATIONYvonne Winhofer, Peter Wolf, Paul Fellinger, et al.
Hepatology (Baltimore, Md.)|May 6, 2008
A randomized, prospective trial of ribavirin 400 mg/day versus 800 mg/day in combination with peginterferon alfa-2a in hepatitis C virus genotypes 2 and 3Peter Ferenci, Harald Brunner, Hermann Laferl, et al.
Pageof 17